Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Puma Biotechnology, Inc.NASDAQ: PBYI
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -8.5%
Operating margin was -8.5% in Q1 FY2026, down 17.2 pp from a year earlier. On a trailing-twelve-month basis it was 13.0%, down 3.0 pp year over year. Over 3 fiscal years it widened by 5.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of 15.9% for the fiscal year ending Dec 2026, down from 16.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -8.5%-31.2 pp QoQ
- Last fiscal yearDec 2025
- 16.3%+2.9 pp YoY
- LTMMar 2026
- 13.0%-3.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.2 pp | -7.1 pp | +10.1 pp |
| 1 year | +2.9 pp | -0.4 pp | -3.3 pp |
| 3 years | +5.9 pp | -7.3 pp | -13.2 pp |
| 5 years | -12.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 16.3%
- Year-over-year change
- +2.9pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.3% | +2.9pp |
| FY2024 | 2024-12-31 | 13.4% | -0.4pp |
| FY2023 | 2023-12-31 | 13.9% | +3.4pp |
| FY2022 | 2022-12-31 | 10.4% | +9.9pp |
| FY2021 | 2021-12-31 | 0.5% | — |
Operating Margin vs competitors
How PBYI compares with its peers on the latest reported figures
- PBYI's LTM Mar 2026 operating margin of 13.0% is the 2nd highest of the 7 companies compared; the peer median is -129.7%.
- Its year-over-year change of -3.0 pp is the 5th highest of 6, against a peer median of +167.7 pp.
- Over three fiscal years its change of +5.9 pp compares with a peer median of +1174.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 28.4% | — | — | |
| LTM Mar 2026 | 13.0% | -3.0 pp | +5.9 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Jun 2026 | -81.0% | +1483.9 pp | — | |
| FY2025 | -178.4% | +167.7 pp | +268.4 pp | |
| LTM Mar 2026 | -344.6% | +966.2 pp | +2259.3 pp | |
| LTM Mar 2026 | -9033.9% | -173.4 pp | +2081.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NBPNovaBridge Biosciences | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding PBYI) | -129.7% | +167.7 pp | +1174.7 pp | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Cost of Revenue | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M |
| Gross Profit | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Gross Margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Research & Development | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Selling, General & Admin | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M |
| Operating Expenses | 188.16M | 149.22M | 140.32M | 135.1M | 132.92M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| EBITDA | (4.69M) | 21.89M | 47.52M | 48.08M | 53.34M |
| EBITDA Margin | -1.9% | 9.6% | 20.2% | 20.9% | 23.4% |
| Operating Income | 1.29M | 23.72M | 32.64M | 30.97M | 37.3M |
| Operating Margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Interest Income | 160K | 813K | 2.61M | 4.72M | 4.08M |
| Interest Expense | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M |
| Other Income / Expenses | (30.09M) | (23.26M) | (9.97M) | (6.87M) | (1.52M) |
| Income Before Tax | (28.8M) | 457K | 22.67M | 24.1M | 35.78M |
| Pre-Tax Margin | -11.4% | 0.2% | 9.6% | 10.5% | 15.7% |
| Income Tax Expense | 324K | 455K | 1.08M | (6.18M) | 4.67M |
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Net Margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (Basic) | (0.72) | 0.02 | 0.46 | 0.62 | 0.62 |
| EPS (Diluted) | (0.72) | 0.02 | 0.45 | 0.62 | 0.61 |
| Weighted Avg Shares | 40.64M | 44.67M | 47.13M | 48.65M | 50.01M |
| Weighted Avg Shares (Diluted) | 40.64M | 44.93M | 47.55M | 49.1M | 50.65M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.